HERON THERAPEUTICS, INC. /DE/ (HRTX) Return on equity 2017–2025
HERON THERAPEUTICS, INC. /DE/ (HRTX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-139.5%FY2025 · since FY2017: -150.6% → -139.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -139.5% | — |
| FY2022 | -1341.0% | -1056.1 pp |
| FY2021 | -284.9% | -188.8 pp |
| FY2020 | -96.1% | -45.4 pp |
| FY2019 | -50.7% | -2.4 pp |
| FY2018 | -48.3% | +102.3 pp |
| FY2017 | -150.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice